This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Is the Future Bleak for SAVA Stock Following Another Setback?
by Zacks Equity Research
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
BIIBNegative Net Change LLYPositive Net Change SAVAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sky Harbour Group Corporation (SKYH) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
SKYHPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar
by Zacks Equity Research
Dr. Reddy's inks collaboration deal with Bio-Thera to develop and commercialize proposed biosimilar candidates of J&J's Stelara and Simponi in Southeast Asia.
RDYNegative Net Change JNJPositive Net Change AMGNPositive Net Change ALVONegative Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
DVAXNegative Net Change BAYRYNegative Net Change CORTNegative Net Change KODPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
by Ekta Bagri
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
ILMNNegative Net Change BEAMPositive Net Change WVEPositive Net Change NTLANegative Net Change CRSPPositive Net Change TWSTPositive Net Change
biotechnology biotechs gene-editing gene-therapy genetic-testing genomics medical
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
by Zacks Equity Research
Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.
BMYNegative Net Change NVOPositive Net Change BAYRYNegative Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
by Zacks Equity Research
Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective targeting of MTAP-deleted tumors.
DVAXNegative Net Change NVOPositive Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
by Zacks Equity Research
Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.
DVAXNegative Net Change BAYRYNegative Net Change CORTNegative Net Change PLRXNegative Net Change
biotechnology biotechs medical pharmaceuticals
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug
by Zacks Equity Research
Soleno's shares soar in the premarket hours following the FDA approval of Vykat XR (diazoxide choline) for treating hyperphagia in PWS patients.
BAYRYNegative Net Change CORTNegative Net Change ACADNegative Net Change SLNONegative Net Change
biotechnology biotechs medical pharmaceuticals
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
by Zacks Equity Research
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
BMYNegative Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More
by Zacks Equity Research
SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.
GSKPositive Net Change ALNYPositive Net Change SAVAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Groupon (GRPN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GRPNNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ADMANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
by Zacks Equity Research
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
BIIBNegative Net Change LLYPositive Net Change GILDNegative Net Change SAVAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation
by Zacks Equity Research
BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff. Stock declines.
NVOPositive Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
by Zacks Equity Research
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
NVOPositive Net Change LLYPositive Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
by Zacks Equity Research
UNITY Biotechnology stock loses 29% as the mid-stage DME study of the lead candidate, UBX1325, fails to achieve statistical significance for the primary goal.
REGNPositive Net Change DVAXNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Top-Ranked Mid-Cap Stocks to Buy for a Stellar Portfolio
by Nalak Das
Five mid-cap stocks have strong revenues and earnings growth potential for 2025. These are: EAT, MAT, CENX, SKYW, ANIP.
MATPositive Net Change EATPositive Net Change SKYWNegative Net Change CENXNegative Net Change ANIPPositive Net Change
airlines biotechnology consumer-discretionary industrial-products restaurants
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?
by Ekta Bagri
AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.
JNJPositive Net Change ACIUNegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
RHHBYPositive Net Change NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy ANI Pharmaceuticals (ANIP) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ANIPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
by Nalak Das
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
ABTNegative Net Change NVSPositive Net Change BSXPositive Net Change LLYPositive Net Change MDTNegative Net Change
biotechnology pharmaceuticals
FDA Approves Novartis Drug for Rare Kidney Disease Treatment
by Zacks Equity Research
Novartis wins FDA approval for the label expansion of Fabhalta for a third indication - treatment of adults with C3 glomerulopathy.
NVSPositive Net Change GILDNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
by Zacks Equity Research
ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
ALNYPositive Net Change NVSPositive Net Change DVAXNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
by Zacks Equity Research
OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
DVAXNegative Net Change GILDNegative Net Change ARVNNegative Net Change
biotechnology biotechs medical pharmaceuticals